> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel Meeting on Alkermes Schizophrenia/Bipolar Drug
- URL: https://www.fdaweb.com/panel-meeting-on-alkermes-schizophrenia-bipolar-drug/
- Published: 2020-08-28T12:00:00.000Z
- Updated: 2026-09-14T16:27:00.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147538

*Federal Register* notice: FDA has announced a 10/9 joint meeting of its Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. Panel members are scheduled to discuss the efficacy, safety, and benefit-risk profile of an Alkermes NDA for olanzapine and samidorphan oral tablets, indicated for treating schizophrenia and bipolar disorder. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-08-28/pdf/2020-18951.pdf?ref=fdaweb.com).